Pharmaceutical Executive
Reoccurring disappointment in development portfolios-why it happens and how to mitigate it.
Gary Summers
Advertisement
Articles by Gary Summers
Advertisement
Latest Updated Articles
Product Development: The Optimizer’s CurseSeptember 19th 2019
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5